Daiichi Sankyo (OTCMKTS:DSNKY) Upgraded at Zacks Research

Daiichi Sankyo (OTCMKTS:DSNKY) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

Separately, Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Daiichi Sankyo has an average rating of “Hold”.

Daiichi Sankyo Price Performance

OTCMKTS:DSNKY opened at $19.00 on Monday. Daiichi Sankyo has a 1 year low of $14.98 and a 1 year high of $27.50. The company has a current ratio of 2.92, a quick ratio of 1.96 and a debt-to-equity ratio of 0.29. The stock has a market cap of $35.39 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 2.61 and a beta of -0.11. The stock has a 50-day moving average price of $17.67 and a two-hundred day moving average price of $17.27.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, equities analysts expect that Daiichi Sankyo will post 0.97 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.